Eszopiclone
Fatal overdose may occur when GABAergic substances are combined with other depressants such as opiates, benzodiazepines, barbiturates, gabapentinoids, thienodiazepines or alcohol.[1]
It is strongly discouraged to combine these substances, particularly in common to heavy doses.
| Summary sheet: Eszopiclone |
| Eszopiclone | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||
| Common names | Lunesta, Eszop | ||||||||||||||||||||||||||||
| Substitutive name | Eszopiclone | ||||||||||||||||||||||||||||
| Systematic name | (S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate | ||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||
| Psychoactive class | Depressant / Hallucinogen | ||||||||||||||||||||||||||||
| Chemical class | Cyclopyrrolone | ||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||
Eszopiclone (also known by the trade names Lunesta) is a non-benzodiazepine hypnotic substance of the cyclopyrrolone class that is primarily used in the treatment of insomnia. Eszopiclone is known to belong to a family of drugs colloquially known as "Z-drugs". Other Z-drugs include Zopiclone (Imovane) zaleplon (Sonata) and zolpidem (Ambien and AmbienCR).
Eszopiclone is thought to increase the normal neurotransmission of the neurotransmitter GABA in the central nervous system in a similar yet distinct way to the activity of benzodiazepines. As Eszopiclone displays heavy sedating effects, it is has been approved for and is commonly sold as a sleeping pill.[citation needed]
While "Z-drugs" were initially thought to have less misuse potential than benzodiazepines, this appraisal has shifted somewhat in the last few years as a number of cases of addiction and habituation have been observed. Eszopiclone, like all "Z-drugs", is recommended to be taken on a short-term basis -- usually a week or less.[2] Daily or continuous use of the drug is usually not advised.Cite error: Closing </ref> missing for <ref> tag
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Depressants (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Dissociatives - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
- United States: On Dec 15, 2004, released eszopiclone as a treatment for insomnia. It is currently a Schedule 4 controlled substance, because it has abuse potential, just as benzodiazepines do. Possession without a prescription can lead to drug charges.